The goal of this activity is for learners to be better able to communicate regarding the management of patients with ER-positive/HER2-negative metastatic breast cancer (MBC) who have recurrence or have progressed on aromatase inhibitor (AI) cyclin-dependent kinase 4/6 (CDK4/6) inhibitors.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 283 - 299 Market St.
Pricing
100% of listed courses are free
300 of a sample of 300 are free · 1,252 courses listed here.
Collected from the provider’s public pages
Specialties served/covered
- Addiction Medicine
- Adolescent Medicine
- Advanced Heart Failure & Transplant Cardiology
- Allergy & Clinical Immunology
- Breast Imaging
- Cardiovascular Disease
- Clinical Cardiac Electrophysiology
- Clinical Informatics
- Communication & Shared Decision-Making
- Critical Care Medicine
- Dermatology
- Diagnostic Radiology
- Emergency Medicine
- Endocrinology, Diabetes & Metabolism
- Facial Plastic & Reconstructive Surgery
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General & Adult Psychiatry
- General Internal Medicine
- General Pediatrics
- Geriatric Medicine
- Gynecologic Oncology
- Health Equity & Inclusion
- Hematology
- Hospice & Palliative Medicine
- Hospital Medicine
- Infectious Disease
- Interventional Cardiology
- Maternal-Fetal Medicine
- Medical Genetics & Genomics
- Medical Oncology
- Metabolic & Bariatric Surgery
- Mood & Anxiety Disorders
- Neonatal-Perinatal Medicine
- Nephrology
- Neurocritical Care
- Neurodevelopmental Disabilities
- Neurology
- Neuromuscular Medicine
- Neuroradiology
- Nuclear Medicine
- Obstetric Anesthesia
- Obstetrics & Gynecology
- Ophthalmology
- Otology & Neurotology
- Pain Medicine
- Patient Education & Health Literacy
- Patient Safety & Quality Improvement
- Pediatric Gastroenterology
- Pediatric Neurology
- Plastic & Reconstructive Surgery
- Preventive Medicine
- Primary Care Sports Medicine
- Pulmonary Disease
- Rheumatology
- Rhinology
- Sleep Medicine
- Transplant Hepatology
- Urological Oncology
- Vascular Neurology
- Anesthesiology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- ENT & Head Neck
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pain & Palliative
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- Sports & Exercise Medicine
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Enduring / On-demand
- Credit · Up to 0.25 credits
- MOC · Up to 0.25 points
- Commercial Support
-
ReleasedFeb 19, 2026
-
Last day to claim creditFeb 20, 2027 4 months left
-
Medscape, LLC Communicating to Enhance Care Through Data and the Patient Experience: ER-Positive/HER2-Negative Metastatic Breast Cancer Edition
-
Medscape, LLC Patients Progressing on an AI +/ CDK4/6 Inhibitors: From Biomarkers to Treatment Strategies
-
Medscape, LLC Cases in the Clinic: Aligning Your Practice to the Evolution of HR-Positive Metastatic Breast Cancer Care
-
Medical Learning Institute, Inc. Nursing Voices from the Frontline: Adjuvant CDK4/6 Therapy in HR+ HER2- Breast Cancer
-
Kaplan Medical Education Can We Do Better? Choosing an Adjuvant CDK4/6 Inhibitor for HR+/HER2- Early Breast Cancer
-
University of Chicago School of Medicine Navigating Complexity in the Post-CDK4/6 Inhibitor Treatment Setting for Patients With ER+/HER2- mBC: Strategies for Optimally Integrating Next-Generation Oral SERDs
